(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 June 2007 (21.06.2007)

PCT

(10) International Publication Number
WO 2007/069977 A1

(51) International Patent Classification:
C07D 215/52 (2006.01) *A61P 25/24* (2006.01)
A61K 31/47 (2006.01) *A61P 25/28* (2006.01)
A61P 25/18 (2006.01) *A61P 3/04* (2006.01)
A61P 25/22 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/SE2006/001408

(22) International Filing Date:
11 December 2006 (11.12.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/749,431 12 December 2005 (12.12.2005) US
60/821,016 1 August 2006 (01.08.2006) US

(71) Applicant *(for all designated States except US)*: **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **SIMPSON, Thomas** [US/US]; AstraZeneca Wilmington, 1800 Concord Pike, P.o. Box 15437, Wilmington, Delaware 19850-5437 (US). **KANG, James** [US/US]; AstraZeneca Wilmington, 1800 Concord Pike, P.o. Box 15437, Wilmington, Delaware 19850-5437 (US). **ALBERT, Jeffrey** [US/US]; AstraZeneca Wilmington, 1800 Concord Pike, P.o. Box 15437, Wilmington, Delaware 19850-5437 (US). **ALHAMBRA, Cristobal** [ES/US]; AstraZeneca Wilmington, 1800 Concord Pike, P.o. Box 15437, Wilmington, Delaware 19850-5437 (US). **KOETHER, Gerard** [US/US]; AstraZeneca Wilmington, 1800 Concord Pike, P.o. Box 15437, Wilmington, Delaware 19850-5437 (US). **WOODS, James** [US/US]; AstraZeneca Wilmington, 1800 Concord Pike, P.o. Box 15437, Wilmington, Delaware 19850-5437 (US). **LI, Yan** [US/US]; AstraZeneca Wilmington, 1800 Concord Pike, P.o. Box 15437, Wilmington, Delaware 19850-5437 (US).

(74) Agent: **ASTRAZENECA**; Global Intellectual Property, S-151 85 Södertälje (SE).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ALKYLSULPHONAMIDE QUINOLINES



(I)

(57) Abstract: Compounds of Formula (1), pharmaceutically-acceptable salts, methods of making them, pharmaceutical compositions containing them and methods for their use. The compounds are neurokinin- 3 (NK-3) receptor antagonists and are used in the treatment of diseases such as depression, anxiety, schizophrenia, cognitive disorders, psychoses, obesity, inflammatory diseases, irritable bowel syndrome, inflammatory bowel disorder, emesis, preeclampsia, chronic obstructive pulmonary disease, disorders associated with excessive gonadotrophins and/or androgens including dysmenorrhea, benign prostatic hyperplasia, prostatic cancer and testicular cancer.

WO 2007/069977 A1